| Literature DB >> 33492719 |
Lonneke A van Vught1,2, Fabrice Uhel1,2, Chao Ding1,2,3, Cees Van't Veer1,2, Brendon P Scicluna1,2,4, Hessel Peters-Sengers1,2, Peter M C Klein Klouwenberg5,6,7, Peter Nürnberg8, Olaf L Cremer5, Marcus J Schultz9,10,11, Tom van der Poll1,2,12.
Abstract
BACKGROUND: A prolonged prothrombin time (PT) is a common feature in sepsis indicating consumptive coagulopathy.Entities:
Keywords: endothelium inflammation; host response; intensive care unit; prothrombin time; sepsis
Year: 2021 PMID: 33492719 PMCID: PMC8048632 DOI: 10.1111/jth.15246
Source DB: PubMed Journal: J Thromb Haemost ISSN: 1538-7836 Impact factor: 5.824
FIGURE 1Flowchart of patient inclusion. ICU, intensive care unit; IV, intravenous; PT, prothrombin time
Baseline characteristics and outcome of patient admissions for sepsis stratified by prothrombin time on admission
| Normal PT | Slightly prolonged PT | Intermediately prolonged PT | Extremely prolonged PT |
| |
|---|---|---|---|---|---|
| PT ≤ 12.7 s | 12.8 ≤ PT ≤ 15.0 s | 15.1 ≤ PT ≤ 17.2 s | PT ≥ 17.3 s | ||
| Patients | 375 | 362 | 367 | 367 | |
| Admissions | 386 | 379 | 383 | 376 | |
| Age, mean (SD) | 59.2 (16.0) | 56.4 (16.7) | 60.0 (15.4) | 61.2 (14.9) | <.001 |
| Race, white, | 308 (82.1%) | 318 (87.8%) | 342 (93.2%) | 340 (92.6%) | <.001 |
| Gender, male, | 237 (63.2%) | 215 (59.4%) | 237 (64.6%) | 224 (61.0%) | .48 |
| Medical admission, | 292 (75.6%) | 280 (73.9%) | 276 (72.1%) | 281 (74.7%) | .06 |
| Chronic comorbidities, | |||||
| None | 143 (38.1%) | 113 (31.2%) | 90 (24.5%) | 87 (23.7%) | <.001 |
| Cardiovascular compromise | 81 (21.6%) | 58 (16.0%) | 77 (21.0%) | 93 (25.3%) | .02 |
| COPD | 62 (16.5%) | 45 (12.4%) | 56 (15.3%) | 43 (11.7%) | .19 |
| Diabetes | 65 (17.3%) | 63 (17.4%) | 76 (20.7%) | 78 (21.3%) | .39 |
| Hypertension | 96 (25.6%) | 92 (25.4%) | 128 (34.9%) | 108 (29.4%) | .02 |
| Immunocompromise | 64 (17.1%) | 84 (23.2%) | 80 (21.8%) | 97 (26.4%) | .02 |
| Malignancy | 49 (13.1%) | 90 (24.9%) | 109 (29.7%) | 115 (31.3%) | <.001 |
| Renal insufficiency | 32 (8.5%) | 32 (8.8%) | 35 (9.5%) | 66 (18.0%) | <.001 |
| Respiratory insufficiency | 73 (19.5%) | 65 (18.0%) | 63 (17.2%) | 56 (15.3%) | .49 |
| Charlson comorbidity index | 4 [2–5] | 4 [2–5] | 4 [3–6] | 4 [2–6] | <.001 |
| Severity of disease on ICU admission | |||||
| APACHE IV Score, median [IQR] | 64 [51–82] | 71 [55–90] | 77 [62–94] | 91 [71–114] | <.0001 |
| APACHE APS median [IQR] | 53 [38–70] | 60 [45–76] | 64 [50–79] | 76 [59–97] | <.0001 |
| SOFA score, median [IQR] | 6 [4–8] | 5 [3–8] | 6 [4–8] | 8 [6–10] | <.0001 |
| Mechanical ventilation, | 270 (69.9%) | 287 (75.7%) | 294 (76.8%) | 298 (79.3%) | .02 |
| Shock, | 55 (14.2%) | 64 (16.9%) | 85 (22.2%) | 154 (41.0%) | <.001 |
| Acute kidney injury, | 114 (29.5%) | 101 (26.6%) | 111 (29.0%) | 191 (50.8%) | <.001 |
| Acute respiratory distress syndrome, | 93 (24.1%) | 73 (19.3%) | 91 (23.8%) | 98 (26.1%) | .15 |
| Source of infection, | |||||
| Pulmonary | 221 (57.3%) | 195 (51.5%) | 195 (50.9%) | 140 (37.2%) | <.001 |
| Abdominal | 37 (9.6%) | 50 (13.2%) | 74 (19.3%) | 104 (27.7%) | <.001 |
| Urinary tract | 31 (8.0%) | 21 (5.5%) | 24 (6.3%) | 35 (9.3%) | .19 |
| Cardiovascular infection | 7 (1.8%) | 10 (2.6%) | 9 (2.3%) | 20 (5.3%) | .02 |
| CNS | 33 (8.5%) | 33 (8.7%) | 22 (5.7%) | 8 (2.1%) | <.001 |
| Skin | 6 (1.6%) | 8 (2.1%) | 4 (1.0%) | 16 (4.3%) | .02 |
| Other | 51 (13.2%) | 62 (16.4%) | 55 (14.4%) | 53 (14.1%) | .63 |
| Causative pathogens, | |||||
| Gram‐positive bacteria | 128 (33.2%) | 132 (36.5%) | 170 (46.3%) | 177 (48.2%) | <.001 |
| Gram‐negative bacteria | 149 (38.6%) | 156 (41.2%) | 172 (44.9%) | 196 (52.1%) | .001 |
| Fungi | 30 (7.7%) | 35 (9.2%) | 36 (10.4%) | 29 (7.7%) | .75 |
| Viruses | 14 (3.6%) | 30 (7.9%) | 15 (3.9%) | 17 (4.5%) | .02 |
| Other | 17 (4.4%) | 19 (5.0%) | 32 (8.4%) | 21 (5.6%) | .24 |
| Unknown | 178 (46.7%) | 165 (43.5%) | 175 (45.7%) | 147 (39.1%) | .18 |
| Outcome | |||||
| Length of stay, median days [IQR] | 3 [2–7] | 3 [2–7] | 4 [2–8] | 5 [2–10] | <.001 |
| ICU‐acquired complications, | |||||
| None | 338 (87.6%) | 345 (91.0%) | 335 (87.5%) | 308 (81.9%) | <.01 |
| Acute kidney injury | 31 (8.0%) | 18 (4.7%) | 22 (5.7%) | 26 (6.9%) | .26 |
| Acute respiratory distress syndrome | 10 (2.6%) | 7 (1.8%) | 21 (5.5%) | 14 (3.7%) | .03 |
| ICU‐acquired infection | 9 (6.0%) | 28 (5.7%) | 34 (7.0%) | 49 (10.3%) | .04 |
| Mortality, | |||||
| ICU mortality | 32 (8.3%) | 51 (13.5%) | 47 (12.3%) | 96 (25.5%) | <.001 |
| Hospital mortality | 67 (17.9%) | 88 (24.3%) | 73 (19.9%) | 132 (36.0%) | <.001 |
| 30‐day mortality | 62 (16.5%) | 78 (21.5%) | 62 (16.9%) | 121 (33.0%) | <.001 |
| 90‐day mortality | 82 (21.9%) | 102 (28.2%) | 95 (25.9%) | 154 (42.0%) | <.001 |
| 1‐year mortality | 113 (30.1%) | 132 (36.5%) | 133 (36.2%) | 186 (50.7%) | <.001 |
Age, race, gender, and chronic comorbidities are provided for unique patients, all other variables are provided for each admission.
In 57 (14.8%) infectious events in normal PT, 61 (16.1%) in slightly prolonged PT, 82 (21.4%) in intermediately prolonged PT, and 75 (19.9%) extremely prolonged PT multiple pathogens were assigned as causative (p = .05).
Mortality, except for ICU mortality, is given for unique patients, all other variables are given for every admission.
Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; APS, Acute Physiology Score; CNS, central nervous system; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; IQR, interquartile ratio; PT, prothrombin time; SD, standard deviation; SOFA, Sequential Organ Failure Assessment.
Significant versus normal PT using a Dunn's test of multiple comparisons using rank sums for nonparametric continues variables, a Tuckey test for parametric continues variables and a Bonferroni correction for categorical variables.
Significant versus slightly prolonged PT using a Dunn's test of multiple comparisons using rank sums for nonparametric continues variables, a Tuckey test for parametric continues variables and a Bonferroni correction for categorical variables.
Significant versus intermediately prolonged PT using a Dunn's test of multiple comparisons using rank sums for nonparametric continues variables, a Tukey test for parametric continuos variables, and a Bonferroni correction for categorical variables.
Cox proportional hazard analyses for 30‐day mortality risk
| Model 1 ‐ unadjusted | Model 2 ‐ adjusted | Model 3 ‐ adjusted | |||
|---|---|---|---|---|---|
| Covariables | HR [95% CI] | Covariables | HR [95% CI] | Covariables | HR [95% CI] |
| Slightly prolonged PT | 1.28 [0.92–1.77] | Slightly prolonged PT | 1.13 [0.81–1.57] | Slightly prolonged PT | 1.11 [0.80–1.55] |
| Intermediately prolonged PT | 1.10 [0.78–1.54] | Intermediately prolonged PT | 0.83 [0.59–1.17] | Intermediately prolonged PT | 0.80 [0.56–1.13] |
| Extremely prolonged PT | 2.21 [1.63–2.98] | Extremely prolonged PT | 1.15 [0.83–1.59] | Extremely prolonged PT | 1.13 [0.81–1.60] |
| Age | 1.02 [1.01–1.02] | Age | 1.02 [1.01–1.02] | ||
| APACHE IV APS | 1.02 [1.02–1.03] | Gender, male | 0.91 [0.73–1.14] | ||
| White race | 1.21 [0.82–1.79] | ||||
| APACHE IV APS | 1.02 [1.02–1.03] | ||||
| Malignancy | 1.32 [1.03–1.69] | ||||
| Immunocompromise | 1.21 [0.93–1.57] | ||||
| Renal compromise | 0.92 [0.67–1.27] | ||||
| Lung infection | 1.38 [1.06–1.78] | ||||
| Abdominal infection | 1.34 [0.97–1.85] | ||||
| Gram negative infection | 0.92 [0.74–1.67] | ||||
| Lowest platelet count first 24 h | 0.999 [0.998–0.999] | ||||
| Fresh frozen plasma units transfused in first 24 h | 0.87 [0.74–1.01] | ||||
Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; APS, Acute Physiology Score; CI, confidence interval; HR, hazard ratio; PT, prothrombin time.
Proportionality was not met for APACHE IV APS.
FIGURE 2Prothrombin time and platelet counts over time in patients with sepsis stratified according to prothrombin time on admission to the intensive care unit (ICU). Data are mean and standard error of the mean. Numbers below x‐axis indicate number of patients still present in the intensive care unit for each group
FIGURE 3Biomarkers reflecting coagulation activation in patients with sepsis stratified according to prothrombin time on admission and matched for discordant baseline parameters. Data are expressed as box and whisker diagrams depicting the median and lower quartile, upper quartile, and their respective 1.5 interquartile range as whiskers (as specified by Tukey). Dotted lines indicate median values obtained in 27 healthy age‐matched subjects. Biomarker distribution on ICU admission was compared using a nonparametric Mann‐Whitney U test. **p < .01, ***p < .001, ****p < .0001. APTT, activated partial thromboplastin time; PT, prothrombin time
FIGURE 4Biomarkers reflecting endothelial cell activation and barrier function in patients with sepsis stratified according to prothrombin time on admission and matched for discordant baseline parameters. Data are expressed as box and whisker diagrams depicting the median and lower quartile, upper quartile, and their respective 1.5 interquartile range as whiskers (as specified by Tukey). Dotted lines indicate median values obtained in 27 healthy age‐matched subjects. Biomarker distribution on intensive care unit admission was compared using a nonparametric Mann‐Whitney U test. **p < .01. ***p < .001. ANG, angiopoietin; sE‐Selectin, soluble E‐selectin; sICAM, soluble intercellular adhesion molecule
FIGURE 5Biomarkers reflecting systemic inflammation in patients with sepsis stratified according to prothrombin time on admission and matched for discordant baseline parameters. Data are expressed as box and whisker diagrams depicting the median and lower quartile, upper quartile, and their respective 1.5 interquartile range as whiskers (as specified by Tukey). Dotted lines indicate median values obtained in 27 healthy age‐matched subjects. Biomarker distribution on intensive care unit admission was compared using a nonparametric Mann‐Whitney U test. **p < .01, ***p < .001. IL, interleukin; MMP, matrix metalloproteinase
FIGURE 6Leukocyte genomic responses and associated biological pathways in patients with sepsis stratified according to prothrombin time on admission and matched for discordant baseline parameters. A, Volcano plot illustrating the differences in leukocyte genomic responses (integrating log2 foldchanges and multiple‐test adjusted probabilities) between sepsis patients with normal PT (PT ≤ 12.7 s) and healthy subjects (left) and patients with extremely prolonged PT (PT ≥ 17.3 s) and healthy subjects (right). Considering adjusted p < .05, 8239 and 8972 genes were identified as differentially expressed in patients with normal PT versus healthy subjects, and patients with extremely prolonged PT versus healthy subjects, respectively. Blue dots represent significantly underexpressed genes (adjusted p < .05, fold expression <−1.2) whereas red dots represent significantly overexpressed genes (adjusted p < .05, fold expression >1.2) in patients relative to healthy controls. Horizontal dotted line indicates multiple‐test adjusted Benjamini‐Hochberg (BH) p < .05 threshold. B, Venn‐Euler representation of differentially expressed genes in sepsis patients with extremely prolonged PT and normal PT versus healthy subjects (adjusted p < .05). Red arrows denote overexpressed genes; blue arrows denote underexpressed genes. C, Dot plot depicting the common response (log2 foldchanges) of patients with extremely prolonged PT and normal PT compared to healthy subjects. r, Spearman's correlation coefficient. D, Volcano plot illustrating the differences in leukocyte genomic responses between sepsis patients with extremely prolonged PT and patients with normal PT upon admission. Considering adjusted p < .05, 277 genes were identified as differentially expressed in patients with extremely prolonged PT versus patients with normal PT. E, Ingenuity pathway analysis of commonly underexpressed genes in patients with extremely prolonged PT versus patients with normal PT. –log (Benjamini‐Hochberg (BH)) p value, negative log10‐transformed p value corrected for multiple comparisons; PPAR, peroxisome proliferator‐activated receptor; PT, prothrombin time; RAR, retinoid acid receptor